Jiexuan Jiang is an immuno-oncology PhD researcher at Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine, where she focuses on engineering next-generation CAR-T cell therapies designed to overcome the immunosuppressive solid-tumour microenvironment.
Jiexuan
Jiang
Venture Fellows
She is a DAAD Graduate School Scholar within the Berlin School of Integrative Oncology. Before her PhD, Jiexuan completed a Master of Research in Translational Cancer Medicine at King’s College London, graduating with distinction, and earned a First-Class Honours BSc in Cancer Biology and Immunology from the University of Bristol.
Alongside her academic work, Jiexuan is the director of programmes at Nucleate Germany, where she leads biotech community initiatives, startup diligence, and founder support. Since November 2024, she has also served as a venture scout for LongeVC, sourcing early-stage healthspan and biotech companies across Europe.
Jiexuan has published on antibody-drug conjugates (ADCs) and contributed to research on target antigen attributes relevant to both haematopoietic and solid-tumour ADC development. Her work spans tumour immunology, cell engineering, translational oncology, and early-stage biotech commercialisation. She is fluent in English, Mandarin, German, and Cantonese.
Alongside her academic work, Jiexuan is the director of programmes at Nucleate Germany, where she leads biotech community initiatives, startup diligence, and founder support. Since November 2024, she has also served as a venture scout for LongeVC, sourcing early-stage healthspan and biotech companies across Europe.
Jiexuan has published on antibody-drug conjugates (ADCs) and contributed to research on target antigen attributes relevant to both haematopoietic and solid-tumour ADC development. Her work spans tumour immunology, cell engineering, translational oncology, and early-stage biotech commercialisation. She is fluent in English, Mandarin, German, and Cantonese.
Washington D.C., US
The Future Belongs to Biotech Founders
© All Rights Reserved, 2025
© All Rights Reserved, 2025
get in touch
social
newsletter
